Psychedelics for depression stories

Jun 22, 2026

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources

Apr 18, 2026

Trump Signs Executive Order to Expedite Psychedelic Drug Review and Reclassification

President Trump signed an executive order directing the FDA to expedite reviews of breakthrough psychedelic therapies for PTSD, depression, and trauma, and to reevaluate their status as controlled substances. The order targets substances including psilocybin.

Apr 18, 2026·3 sources

Top claims

▪The drug functions by activating serotonin receptors in the brain.
▪DT120 is classified as a classic psychedelic, a type of drug that temporarily alters perception, mood, and thinking.
▪Definium Therapeutics announced its LSD-based pill, DT120, significantly reduced major depression symptoms in a late-stage trial.

People involved

Donald Trump

Subtopics

LSD Psychedelic clinical research & trials Depression Psychedelic renaissance

Psychedelic policy & regulation

Psilocybin

Psychedelics for PTSD

Related timelines

Psychedelics for depression stories

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Trump Signs Executive Order to Expedite Psychedelic Drug Review and Reclassification

Related timelines

US Congress

Venture capital funding

Iran War

Strait of Hormuz blockage

Trump administration